Research programme: difluoro anticancer therapeutics - Advanomics

Drug Profile

Research programme: difluoro anticancer therapeutics - Advanomics

Alternative Names: Adva-33c; Carbon-difluoro derivatives - Advanomics; Carboplatin analogue - Advanomics; Difluoro-Carboplatin

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Advanomics
  • Class Fluorinated hydrocarbons; Platinum complexes; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Canada (IV)
  • 28 Oct 2010 Preclinical trials in Cancer in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top